NCT05169944View on ClinicalTrials.gov

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Brain CancerMalignant Brain TumorRecurrent Brain TumorProgressive Malignant Brain TumorBrain Tumor, PediatricBrain Tumor Adult
Interventions
DRUG

Magrolimab

Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis

Trial Locations (3)

84112

Huntsman Cancer Institute, Salt Lake City

84113

University of Utah, Salt Lake City

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors | Biotech Hunter | Biotech Hunter